The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Takeda. The supporters have no influence over the production of the content.
VJHemOnc presents the Waldenström’s Macroglobulinemia Channel
Welcome to the Waldenström’s Macroglobulinemia Channel, bringing you the latest data from world-renowned experts on Waldenström’s macroglobulinemia through exclusive interviews, podcasts, roundtable discussions, and more.
Explore the latest advances, such as rituximab and proteasome inhibitor-based therapies that have demonstrated efficacy in symptom management, and targeted therapies that are increasingly playing a role in tailoring treatment options, directly from leading experts on the Waldenström’s Macroglobulinemia Channel.